CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 193 enrolled
Drug / intervention
QVA149 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01529632
NCT01529632Phase 3Completed
CompareCT.gov

A Study to Compare the Efficacy and Safety of Once Daily QVA149 Versus the Once Daily Concurrent Administration of QAB149 Plus NVA237 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Novartis Pharmaceuticals·interventional·Posted Feb 9, 2012·Updated Feb 12, 2014

In Brief

A Phase 3 clinical trial evaluating QVA149, NVA237, and 2 other interventions for Chronic Obstructive Pulmonary Disease. Completed, enrolled 193 participants across 26 sites in 5 countries.

Detailed Summary

The study assessed the safety and efficacy of the fixed combination product QVA149 versus the component products QAB149 and NVA237, administered concurrently, in patients that have moderate to severe chronic obstructive pulmonary disease (COPD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesAustria, Denmark, Netherlands, Norway, Sweden
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 9, 2012
Enrollment StartMay 1, 2012
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.4 years ago

Interventions

QVA149drug

QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily

NVA237drug

NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily

QAB149drug

QAB149 150 ug supplied as capsules in blister packs for inhalation via SDDPI , once daily

Placebodrug

Placebo capsules provided in blister packs for inhalation via SDDPI, once daily